SynthesisBMC pulmonary medicine2026
The optimal duration of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer: a systematic review of clinical trials.
Wei Guo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.